Sign in

    Matthew L. Trerotola

    CEO and Chair of the Board at Enovis Corp
    Board
    Since July 2015
    Age
    57 years
    Education
    Holds a Master of Business Administration from Harvard Business School and a Bachelor of Science in Chemical Engineering from the University of Virginia.
    Tenure
    Joined as Chief Executive Officer in July 2015 and currently serves as Chair of the Board, after holding key leadership roles at DuPont and Danaher Corporation.

    Also at Enovis Corp

    BRS
    Brady R. Shirley
    Executive Advisor
    DAP
    Daniel A. Pryor
    Executive Vice President, Strategy and Business Development
    LV
    Louis Vogt
    Group President, Reconstructive

    About

    Matthew L. Trerotola has been at the helm of Enovis Corporation since July 2015, where he serves as both Chief Executive Officer and Chair of the Board. His leadership at ENOV marks a significant phase in the company’s development, with his appointment driving strategic changes and growth initiatives.

    Before joining ENOV, he built a robust career through senior roles at several prestigious companies. At DuPont, he served as an Executive Vice President responsible for the Electronics & Communications and Safety & Protection segments, along with oversight of the Asia-Pacific business. Earlier roles at Danaher Corporation, including Vice President and Group Executive for Life Sciences, as well as positions leading product identification and business operations, further showcase his extensive experience in the industry.

    In addition to his executive roles, he is an active board member of AptarGroup, Inc., highlighting his broader influence in the corporate world. With a strong educational foundation from Harvard Business School and the University of Virginia, his career reflects a blend of advanced business acumen and technical expertise, positioning him as a seasoned leader in both operational and strategic capacities.

    $ENOV Performance Under Matthew L. Trerotola

    Past Roles

    OrganizationRoleDate RangeDetails
    DuPont Executive Vice President and Member of the Office of the Chief Executive 2013 – 2015 Oversaw the Electronics & Communications and Safety & Protection segments and managed the Asia-Pacific business
    Danaher Corporation Vice President and Group Executive for Life Sciences 2012 – 2013 Held a leadership role focusing on strategic development in life sciences
    Danaher Corporation Group Executive, Product Identification 2009 – 2012 Focused on product identification and strategic guidance
    Danaher Corporation President of the Videojet Business 2007 – 2009 Led the Videojet business with emphasis on innovation and market growth
    McKinsey & Company Consultant 1995 – 1999 Advised industrial companies to accelerate growth

    External Roles

    OrganizationRoleDate RangeDetails
    AptarGroup, Inc. Director 2022 – Present Active role outside of ENOV

    Fixed Compensation

    Data from  FY 2023
    Component NameAmountPayment ScheduleAdditional Details
    Base Salary $1,077,000AnnualFixed annual base salary
    Company 401(k)/Deferred Compensation Plan Match and Contribution $129,442AnnualIncludes both match and contribution components
    Auto Allowance $20,000AnnualAnnual cash allowance for car-related expenses pursuant to his employment contract
    Financial Services $15,250AnnualReimbursement for financial planning services
    Aircraft Usage $282,344AnnualCompany expenses incurred for private plane usage for personal travel; billed directly
    Supplemental Long-Term Disability Premiums $6,472AnnualPremium payments for supplemental long-term disability insurance
    Group Term Life Insurance $8,748AnnualPremiums for a life insurance benefit equal to 1.5 times salary, capped at $1,125,000

    Performance Compensation

    Data from  FY 2023

    Performance-Based Restricted Stock Units (PRSUs)

    ParameterValueDetails
    MetricRelative Total Shareholder Return (TSR) vs. S&P 500 Health Care Equipment & Supplies Industry Index Determines the payout scale based on percentile performance
    Payout ScaleBelow Threshold: 0%; Threshold (30th percentile): 50%; Target (55th percentile): 100%; Maximum (>80th percentile): 200% (capped at 100% if absolute TSR is negative) Detailed performance brackets
    Grant DateFebruary 28, 2023 The date the award was granted
    Grant Date Fair Value$4,052,607 The fair value assigned on the grant date
    Grant Date Stock Price$57.62 per share Reflects the exercise price for related stock options
    Number of PRSUsThreshold: 28,222; Target: 56,443; Maximum: 112,886 Varies by performance outcome
    VestingCliff vest at end of a three-year performance period Contingent upon certification by the CHCM Committee

    Annual Incentive Plan (AIP)

    ParameterValueDetails
    Performance Metric 1Net Sales (as adjusted) Weight: 40%; Threshold: $1.588 billion; Target: $1.654 billion; Maximum: $1.786 billion; Achieved: $1.693 billion; CPF: 123%
    Performance Metric 2Adjusted EBITDA Weight: 60%; Threshold: $228 million; Target: $260 million; Maximum: $325 million; Achieved: $269 million; CPF: 121%
    Weighted Aggregate CPF122% Combined corporate performance factor
    Bonus CalculationBase Salary: $1,077,000; Target Bonus Percentage: 125%; Target Bonus: $1,346,250; Bonus Before IPF: $1,642,425; Individual Performance Factor: 110%; Executive Bonus Payment: $1,806,668 Bonus metrics derived from performance results
    Equity Grant DetailsPRSUs: $4,052,607; RSUs: $1,626,094; Stock Options: $1,750,010 Grant Date: February 28, 2023; Stock Options vest ratably over three years starting on February 28, 2024

    *Note: All performance compensation metrics reflect the 2023 awards with performance evaluations based on both operational and financial targets, and vest over varying periods as noted above. *